Jubilant Pharmova · NSE: JUBLPHARMA · BSE: 530019

Q2 FY22 results · Jul–Sep 2021

Jubilant Pharmova reported revenue from operations of ₹1,657.45 crore (down 30.2% from Q2 FY21) and net profit of ₹142.64 crore (down 36.4% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	1,657.45	2,374.89	−30.2%	1,634.65	+1.4%
Other income	4.45	7.28	−38.9%	3.89	+14.4%
Total income	1,661.90	2,382.17	−30.2%	1,638.54	+1.4%
Profit before share of associates & JVs and tax	209.43	313.67	−33.2%	256.47	−18.3%
Share of profit/(loss) of associates & JVs	(1.39)	0.00		(9.96)
Net profit for the period	142.64	224.12	−36.4%	160.49	−11.1%
Attributable to shareholders of the company	142.84	224.03	−36.2%	160.56	−11.0%
EPS, basic (₹)	8.97	14.06	−36.2%	10.09	−11.1%
Net margin (%)	8.6	9.4		9.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q2 FY22	Q2 FY21	YoY	Q1 FY22	QoQ
Revenue from operations	20.03	760.75	−97.4%	20.26	−1.1%
Other income	106.08	12.89	+723.0%	4.11	26x
Total income	126.11	773.64	−83.7%	24.37	+417.5%
Profit before tax	94.12	75.23	+25.1%	(1.51)	Turned profit
Net profit for the period	88.08	62.63	+40.6%	(1.13)	Turned profit
EPS, basic (₹)	5.53	3.93	+40.7%	0.07	79x
Net margin (%)	439.7	8.2		-5.6

Consolidated

Filed with BSE: 22 Oct 2021, 18:52 IST
Board meeting: 22 Oct 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 22 Oct 2021, 18:52 IST
Board meeting: 22 Oct 2021
Period: 01 Jul 2021 to 30 Sep 2021
Review status: Unaudited
Source: XBRL filing on BSE